March 22, 2024Cancer Research

CD19 CAR-T Cell Efficacy and Activation in Disseminated Human B-Cell Acute Lymphoblastic Leukemia

View Full Paper

Ask AI

Bookmark

CD19 CAR-T cell therapy combined with ibrutinib extends time to progression by 138.4% compared to controls in a human B-cell acute lymphoblastic leukemia model.
Flow cytometry showed blood CAR-T counts reached 51 cells/µL with ibrutinib by Day 39, while ddPCR analysis confirmed CAR copy numbers increased to 23.3 per ng DNA.
The findings support combining CD19 CAR-T cells with ibrutinib for B-cell acute lymphoblastic leukemia; mouse model limits require further preclinical testing.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Preclinical animal study demonstrates enhanced CD19 CAR-T cell efficacy with ibrutinib in leukemic mice, indicating tumor-dependent expansion and improved leukemia control.

Cite This Study

Pandey et al. (2024) studied this question.

synapsesocial.com/papers/68e72f4bb6db6435876a889b https://doi.org/10.1158/1538-7445.am2024-4002

View Full Paper

Ask AI

Bookmark

Implication

Preclinical animal study demonstrates enhanced CD19 CAR-T cell efficacy with ibrutinib in leukemic mice, indicating tumor-dependent expansion and improved leukemia control.

CD19 CAR-T Cell Efficacy and Activation in Disseminated Human B-Cell Acute Lymphoblastic Leukemia

Key Points

Discussion

Implication

Cite This Study

CD19 CAR-T Cell Efficacy and Activation in Disseminated Human B-Cell Acute Lymphoblastic Leukemia

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider